Clinical trials: HiV1- Positive
HIV Infections
Effects on the Immune System of Anti-HIV Drugs in Patients Recently Infected With HIV
The purpose of this study is to find out whether these powerful combinations of anti-HIV drugs are safe and effective for use in patients in the early stages of HIV infection and to find out how patients' immune systems react to…
- Trial name
- NCT00001119
- Testing
- Tetanus Toxoid Vaccine, Indinavir sulfate, Lamivudine/Zidovudine
- Where
- 12 sites in United States, Australia
- Volunteers
- 288 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV-1 Infection, Tuberculosis
Raltegravir Versus Efavirenz in Naive HIV-1-infected Patients Receiving Rifampin for Active Tuberculosis
Phase III trial evaluating raltegravir as an alternative to efavirenz for antiretroviral treatment of HIV-infected patients with tuberculosis.
- Trial name
- REFLATE TB2 (NCT02273765)
- Testing
- Tenofovir + lamivudine + raltegravir, Tenofovir + lamivudine + efavirenz
- Where
- 5 sites in Brazil, Côte d’Ivoire and 3 more
- Volunteers
- 460 people
- Sponsor
- ANRS, Emerging Infectious Diseases
HIV Infection
A Study of Patient Management in HIV-1 Infected Patients Found to Have the Genetic Marker HLA-B*5701
This is a retrospective observational study which follows on from CNA106030 (a study evaluating whether prospective genetic screening for HLA-B*5701 can reduce the incidence of hypersensitivity reactions to abacavir).
- Trial name
- NCT00435838
- Testing
- No Intervention -- Observational study
- Where
- 25 sites in Austria, Belgium and 5 more
- Volunteers
- 35 people
- Sponsor
- GlaxoSmithKline
HIV, HIV Infections
Efficacy of Tenofovir Alafenamide Versus Placebo Added to a Failing Regimen Followed by Treatment With Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Atazanavir in HIV-1 Positive, Antiretroviral Treatment-Experienced Adults
The primary objective of this study is to evaluate the efficacy of tenofovir alafenamide (TAF) versus placebo, each administered with the existing, failing antiretroviral (ARV) regimen.
- Conditions
- HIV, HIV Infections, Acquired Immunodeficiency Syndrome
- Trial name
- NCT01967940
- Testing
- TAF, E/C/F/TAF, Current failing ARV regimen
- Where
- 15 sites in United States, Dominican Republic and 3 more
- Volunteers
- 55 people
- Sponsor
- Gilead Sciences
HIV Infections
The Effects of Giving Interleukin-2 (IL-2) Plus Anti-HIV Therapy to HIV-Positive Patients With CD4 Cell Counts of at Least 350 Cells/mm3
The purpose of this study is to evaluate the safety and tolerability of giving IL-2 plus anti-HIV (antiretroviral) therapy to HIV-positive patients with CD4 cell counts (cells of the immune system that fight infection) of at…
- Trial name
- NCT00000825
- Testing
- Aldesleukin
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Study Evaluating Vaccine in Adults With HIV
The main purpose of this study is to learn whether the study vaccine and the adjuvants(drugs that are used to help immune response) have an acceptable safety profile in treating individuals with HIV.
- Trial name
- NCT00195312
- Testing
- HIV-1 gag DNA (formulated with bupivacaine), IL-15 DNA (formulated with bupivacaine), IL-12 DNA (formulated with bupivacaine)
- Where
- 13 sites in United States, Germany and 1 more
- Volunteers
- 91 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Mycobacterium Avium-intracellulare Infection, HIV Infections
A Study to Learn More About MAC Disease and the Use of Anti-HIV Drugs in Patients With Advanced HIV Infection
The purpose of this study is to determine if infection with Mycobacterium avium complex (MAC) occurs in other parts of the body before it is found in the blood.
- Trial name
- NCT00000895
- Testing
- Nelfinavir mesylate, Nevirapine, Azithromycin
- Where
- 26 sites in United States
- Volunteers
- 85 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
The CogNaive Study: Assessing Changes in Neurocognitive Function in Treatment Naïve HIV-1 Positive Subjects
The purpose of this study is to investigate the possibility of an association between changes in neurocognitive function, as measured by a computerised test battery, and the use of two different highly active antiretroviral…
- Trial name
- NCT00540137
- Testing
- nevirapine, atazanavir/ritonavir
- Where
- 2 sites in United Kingdom
- Volunteers
- 21 people
- Sponsor
- Imperial College London
HIV-1-infection, Tuberculosis
A Clinical Study Investigating Rifampicin and Dolutegravir in Combination in Healthy Volunteers
The purpose of the study is to see how the drug Dolutegravir is broken down by your body, when taken with another drug called Rifampicin. Dolutegravir is given to people as a treatment for HIV.
- Trial name
- RADIO (NCT03199690)
- Testing
- Dolutegravir, Rifampicin
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- St. Stephens Clinical Research
HIV-1
Long Term Follow-Up Study of Human Immunodeficiency Virus Type 1 (HIV-1) Positive Patients Who Have Received OZ1 Gene Therapy as Part of a Clinical Trial
The purpose of this Observational Study is long term follow-up of the Human Immunodeficiency Virus -1 (HIV-1) infected patients who have received a gene therapy product (anti-HIV-1 Ribozyme [OZ1]) as part of an earlier phase 2…
- Trial name
- NCT01177059
- Testing
- OZ1 transduced cells
- Where
- 6 sites in United States, Australia
- Volunteers
- 68 people
- Sponsor
- Janssen-Cilag Pty Ltd
Hiv, HIV Infections
Long-Acting Treatment in Adolescents (LATA)
The LATA trial will find out if taking a long-acting injectable form of HIV medicines, called cabotegravir and rilpivirine, every 2 month works as well as taking tablet HIV medicines every day in young people aged 12-19 years of…
- Conditions
- Hiv, HIV Infections, HIV-1-infection, Paediatric Human Immunodeficiency Virus Infection
- Trial name
- LATA (NCT05154747)
- Testing
- Cabotegravir, Rilpivirine Drug Combination, TLD
- Where
- 5 sites in Kenya, South Africa and 2 more
- Volunteers
- 476 people
- Sponsor
- University College, London
HIV Infections
The Biology of HIV Transmission
The purpose of this study is to look at the amount of HIV in the blood, genital fluid, and saliva of the partners of patients with early HIV infection.
- Trial name
- NCT00001092
- Where
- 3 sites in United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Tuberculosis Meningitis, HIV-1-infection
Linezolid, Aspirin and Enhanced Dose Rifampicin in HIV-TBM
LASER-TBM is a parallel group, randomized, multi-arm phase IIa trial evaluating the safety of increased dose rifampicin (RIF) plus linezolid (LZD), with or without aspirin (ASA), for the treatment of HIV-infected adults with…
- Trial name
- LASER-TBM (NCT03927313)
- Testing
- Linezolid, High dose rifampicin, Aspirin
- Where
- 4 sites in South Africa
- Volunteers
- 52 people
- Sponsor
- University of Cape Town
HIV Infections
A Study of Ritonavir (an Anti-HIV Drug) in HIV-Positive Infants and Children
The study examines the safety and effectiveness of ritonavir (an anti-HIV drug), alone and in combination with other anti-HIV drugs, in HIV-positive children under 2 years of age.
- Trial name
- NCT00000952
- Testing
- Ritonavir, Lamivudine, Zidovudine
- Where
- 12 sites in United States
- Volunteers
- 60 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Tuberculosis, HIV I Infection
Early Empiric Anti-Mycobacterium Tuberculosis Therapy for Sepsis in Sub-Saharan Africa
In sub-Saharan Africa, tuberculosis (TB) is the etiology of 25-50% of bloodstream infections (BSIs) and the leading cause of sepsis among people living with HIV.
- Conditions
- Tuberculosis, HIV I Infection, Sepsis
- Trial name
- ATLAS (NCT04618198)
- Testing
- Immediate anti-TB therapy, Sepsis-specific dose anti-TB therapy
- Where
- 2 sites in Tanzania, Uganda
- Volunteers
- 437 people
- Sponsor
- University of Virginia
HIV-1 Infection
Analytical Treatment Interruption in HIV Positive Patients
HIV-1 infected patients with normal peripheral blood CD4+ T-cell counts and undetectable viral load will be recruited in four Belgian HIV reference centers.
- Trial name
- ISALA (NCT02590354)
- Testing
- ART interruption
- Where
- 4 sites in Belgium
- Volunteers
- 114 people
- Sponsor
- Institute of Tropical Medicine, Belgium
HIV-1 Infection
Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDF
This study will evaluate the efficacy of switching from emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) fixed dose combination (FDC) to emtricitabine/tenofovir alafenamide (F/TAF) FDC in HIV-1 positive participants who are…
- Trial name
- NCT02121795
- Testing
- FTC/TDF, F/TAF, Allowed third antiretroviral agent
- Where
- 78 sites in United States, Belgium and 5 more
- Volunteers
- 668 people
- Sponsor
- Gilead Sciences
HIV-1 Infection
Switch Study to Evaluate F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed on Regimens Containing ABC/3TC
The primary objectives of this study are to evaluate the efficacy, safety, and tolerability of switching abacavir/lamivudine (ABC/3TC) fixed-dose combination (FDC) tablets to emtricitabine/tenofovir alafenamide (F/TAF) FDC…
- Trial name
- NCT02469246
- Testing
- F/TAF, ABC/3TC, 3rd ARV agent
- Where
- 80 sites in United States, Belgium and 10 more
- Volunteers
- 567 people
- Sponsor
- Gilead Sciences
HIV Infections
RHIV A Pilot Study Refractory or Intolerant to Highly Active Antiretroviral Therapy (HAART)
The objectives of this clinical trial are to: Assess the safety of using extracorporeal photoimmune therapy with the photosensitizing agent Uvadex in the treatment of HIV-1 infection; Evaluate the effects of this therapy on HIV-1…
- Trial name
- HIV-HAART (NCT00157027)
- Testing
- Extracorporeal photochemotherapy with UVADEX
- Sponsor
- Atlantic Health System
HIV Infection
Efficacy of Simplified Two Drug Kaletra Regimen vs. Kaletra Triple Drug Standard of Care Regimen in Treatment naïve HIV Infected Patients
The purpose of this study is to obtain a preliminary assessment of the antiviral activity and tolerability of simplified Kaletra dual agent therapy as initial treatment for HIV infection, relative to a Kaletra three drug standard…
- Trial name
- KALEAD (NCT00234910)
- Testing
- Tenofovir DF, lopinavir/ritonavir with 2 Nucleoside RTIs
- Where
- United States
- Volunteers
- 152 people
- Sponsor
- Abbott